The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00971698|
Recruitment Status : Completed
First Posted : September 4, 2009
Last Update Posted : August 26, 2011
The spleen in Sickle Cell Anemia and Sickle Cell Thalassemia is usually enlarged in the first years of life but the immune protection provided is considered insufficient. In homozygous Sickle cell patients the spleen usually developed recurrent infarcts and after the first decade of age become fibrotic. Acute splenic sequestration is also frequent in those patients and this is considered as an indication for splenectomy.
In comparison in Sickle cell thalassemia patients, hypersplenism is more frequent.
The purpose of this study is to compare the clinical and laboratory issues related to the spleen in two groups of Sickle cell patients.
|Condition or disease|
|Sickle Cell Anemia Thalassemia|
Clinical and laboratory characteristics related to the spleen in SCA patients will be studied.
Two groups of patient will be compared, a group of Sickle cell patients (Homozygous) and a second group of patients with Sickle cell beta thalassemia.
In those patients that splenectomy was performed the incidence of infections will be recorded besides the indications for splenectomy and the incidence of thrombotic events or thrombocytosis.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia. Clinical Presentation and Follow up. Splenectomy, Indications and Complications.|
|Study Start Date :||February 2009|
|Actual Primary Completion Date :||August 2010|
|Actual Study Completion Date :||August 2010|
Sickle Cell Patients
Patients with homozygous Sickle Cell Anemia
Sickle Cell Thalassemia
Patients with Sickle Cell Thalassemia
- Clinical events and abnormal laboratory results [ Time Frame: One year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00971698
|Pediatric Hematology Unit and Pediatric Dpt B - HaEmek Medical Center|
|Afula, Israel, 18101|